Rapid technological advances in DNA sequencing are facilitating the perception that whole-genome sequencing (WGS) will soon be available as a routine clinical diagnostic-and predictive-test. Current clinical testing is typically diagnostic, focusing on single genes or small gene panels, identifying a small number of variants per patient, and yet requiring nontrivial effort and expertise to deliver a clinical laboratory report. Interpreting WGS results will increase the necessary effort exponentially. How will this work in actual practice?
In a recent Science Policy Forum (1 ), Radoje Drmanac promotes WGS as a research tool that will enhance disease diagnosis, prevention, and management by providing a more "comprehensive" method of genetic testing. WGS is touted as better for assessing disorders that have an apparent genetic etiology but that are not amenable to current methods, including those caused by noncoding variants, interaction between multiple variants across the genome, or variants in regulatory regions. Unfortunately, our current level of understanding precludes a clinical interpretation of most noncoding variants.
Beyond providing more data, WGS has been proposed as a mechanism to enhance the efficiency of medical care. Genetic details from a person's WGS test would be stored in the electronic medical record and accessed as needed according to that person's age or underlying medical conditions. Combined with automated clinical-interpretation updates, WGS could minimize the use of purportedly less efficient targeted genetic tests, thereby lowering healthcare costs and improving research at the same time. Drmanac concedes some limitations of WGS, but not to an extent that would make anyone doubt that WGS is ready for the clinic.
Liam Brunham and Michael Hayden, in the same Science issue, provide a somewhat more cautious perspective (2 ) . Interpreting WGS on a large scale requires bioinformatics skills that are currently in short supply, but when such skills do become more available, they will require compensation that will add to the cost of interpretation. If that hurdle can be overcome, we will face a shortage of capable clinicians who can translate voluminous WGS results into rational medical interventions, given that every genome likely contains 150 000 novel single-nucleotide variants, including 250 -300 disruptive variants in genes, 50 -100 variants in human disease genes, and 20 mutations predicted to completely inactivate genes. Most clinical laboratories are approaching this problem by reporting only variants thought to explain the indication for testing, but the best approach is still being defined.
Laboratories and clinics that use WGS will require clear policies to govern decisions about what to report. Brunham and Hayden propose dividing variants into 2 categories: (a) variants with established clinical importance for which the medical implications are clear, such as variants in the BRCA 5 (breast cancer) genes or the APC (adenomatous polyposis coli) gene; and (b) clinically important variants not associated with welldefined medical intervention, such as mutations in the Huntington disease gene, yet requiring special precounseling and a consent form. Although such subcategorization sounds good, in actual practice many ambiguous variants will be identified. Recently, the American College of Medical Genetics and Genomics released a policy statement proposing mandatory preand posttest counseling and a formal consent process to help address some of this ambiguity (3 ).
After reading both articles, one comes away with a clear idea of why WGS is a very powerful research tool, but that sense is tempered by some skepticism about how soon WGS will be ready for widespread clinical implementation. WGS will undoubtedly be a clinical test, but we should be cautious about what can be delivered now. Past promises that sequencing of the human genome would soon lead to rapid breakthroughs in disease prevention and treatment have not yet been realized, so the WGS community should be careful about sweeping claims. Many proposed benefits, such as automated interpretation updates, are not routinely available for current single-gene tests, and the current payer system provides no mechanism for the reimbursement of such services. Providing appropriate counseling services and medical care, given the implications of voluminous results, requires additional healthcare resources beyond the cost of the test itself.
These 2 articles agree on the need for not only robust technical and interpretive standards but also attention to sensitive ethical issues, such as genetic privacy, so that we "do no harm." Over the long term, WGS could achieve the broad health impact that many believe it will. In the short term, there is much work to be done. 
